AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 17 - (NewsRx.com & NewsRx.net) -- Cellegy Pharmaceuticals, Inc., announced promising results of an in vitro study using nitric oxide (NO) donors to decrease resistance of cancer cells to chemotherapeutic drugs.
The paper was authored by Dr. Charles Graham and his coinvestigators at Queen's University, Kingston, Ontario, Canada. Graham is a consultant to Cellegy Pharmaceuticals and is one of the inventors of patent applications filed by Vaxis Therapeutics Corporation on the use of nitric oxide donors for the prevention and treatment of cancer. These patent applications are now part of Cellegy's intellectual property portfolio through the company's recent acquisition of Vaxis.
In the paper, Graham reported that cancer cells (human breast cancer cells, MDA-MB-231, and mouse melanoma cells, B16F10) made resistant to chemotherapeutic agents, 5-fluorouracil and doxorubicin by causing them to become hypoxic following ...
Source: HighBeam Research, Nitric Oxide Donor Reverses Drug Resistance In Breast Cancer and...